JPMorgan Chase & Co. Boosts United Therapeutics (NASDAQ:UTHR) Price Target to $300.00

United Therapeutics (NASDAQ:UTHR - Free Report) had its target price upped by JPMorgan Chase & Co. from $280.00 to $300.00 in a report published on Tuesday morning, Benzinga reports. They currently have an overweight rating on the biotechnology company's stock.

Other analysts have also issued research reports about the stock. The Goldman Sachs Group boosted their price target on shares of United Therapeutics from $218.00 to $240.00 and gave the company a neutral rating in a research note on Friday, May 3rd. Wedbush reaffirmed an outperform rating and issued a $308.00 price target on shares of United Therapeutics in a research report on Thursday, February 22nd. Leerink Partnrs reiterated an outperform rating on shares of United Therapeutics in a research note on Monday, February 5th. SVB Leerink began coverage on United Therapeutics in a research note on Monday, February 5th. They issued an outperform rating and a $330.00 price objective for the company. Finally, Oppenheimer lifted their target price on United Therapeutics from $375.00 to $400.00 and gave the company an outperform rating in a research report on Thursday, May 2nd. One investment analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, United Therapeutics has an average rating of Buy and an average price target of $309.44.

United Therapeutics Stock Up 0.2 %

Shares of UTHR traded up $0.52 during trading hours on Tuesday, hitting $275.19. The stock had a trading volume of 317,142 shares, compared to its average volume of 458,997. United Therapeutics has a 1-year low of $204.44 and a 1-year high of $279.98. The firm has a market capitalization of $12.21 billion, a P/E ratio of 13.01 and a beta of 0.54. The firm has a 50 day simple moving average of $245.08 and a 200-day simple moving average of $233.08. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.77 and a quick ratio of 3.64.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.63 by $0.54. The business had revenue of $677.70 million for the quarter, compared to analyst estimates of $620.31 million. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The company's quarterly revenue was up 33.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $4.86 earnings per share. Sell-side analysts predict that United Therapeutics will post 24.2 EPS for the current fiscal year.

Insider Buying and Selling

In other United Therapeutics news, Director Christopher Causey sold 2,240 shares of the company's stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $259.91, for a total value of $582,198.40. Following the completion of the transaction, the director now owns 4,185 shares in the company, valued at approximately $1,087,723.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other United Therapeutics news, Director Christopher Causey sold 2,240 shares of the business's stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $259.91, for a total value of $582,198.40. Following the transaction, the director now directly owns 4,185 shares in the company, valued at $1,087,723.35. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Martine A. Rothblatt sold 3,600 shares of the firm's stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $272.37, for a total transaction of $980,532.00. Following the sale, the director now owns 130 shares of the company's stock, valued at approximately $35,408.10. The disclosure for this sale can be found here. Over the last three months, insiders have sold 153,740 shares of company stock worth $37,031,694. 12.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Norges Bank purchased a new stake in United Therapeutics during the fourth quarter valued at about $100,519,000. Swedbank AB purchased a new stake in shares of United Therapeutics during the 1st quarter valued at approximately $97,316,000. Nordea Investment Management AB boosted its holdings in United Therapeutics by 677.6% in the 1st quarter. Nordea Investment Management AB now owns 300,920 shares of the biotechnology company's stock worth $72,422,000 after buying an additional 262,222 shares during the period. Avidity Partners Management LP purchased a new position in United Therapeutics in the 4th quarter valued at approximately $52,158,000. Finally, Canada Pension Plan Investment Board raised its holdings in United Therapeutics by 567.2% during the 1st quarter. Canada Pension Plan Investment Board now owns 180,800 shares of the biotechnology company's stock valued at $41,533,000 after acquiring an additional 153,700 shares during the period. Hedge funds and other institutional investors own 94.08% of the company's stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.